PlainPharmaWatch

CMS Open Payments · Program Year 2024

Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc. reported $88,597,173.74 across General Payments, Research, and Ownership to 33,496 physicians and teaching hospitals across 34,372 transactions.

See the rankings → How this is sourced
$88.6M Top 10% payer
All-tracks total
34,372 Top 10% volume
Transactions
33,496 Top 10% reach
Recipients
−$44.6M
General Payments vs PY2023

Zimmer Biomet Holdings, Inc. reported $88,597,173.74 across all CMS Open Payments tracks (General + Research + Ownership) to 33,496 physicians and teaching hospitals in Program Year 2024 - ranking #32 of 1,925 reporting manufacturers (0.6% of the all-tracks industry total); General Payments alone were $83,904,351.23, averaging $2.6K per recipient.

How Zimmer Biomet Holdings, Inc.'s $88.6M all-tracks total breaks down

Zimmer Biomet Holdings, Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

A

100/100

Total payments

A

100/100

Transaction volume

A

100/100

Physician reach

A

100/100

Payment type diversity

A

100/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer zimmer-biomet-holdings-inc Zimmer Biomet Holdings, Inc.

$88.6M · #32/1,925 · 0.6% industry · PY2024

  • TOT $88.6M
  • RANK #32
  • SHARE 0.6%
  • TXN 34,372
  • RCP 33,496
  • CAT 11
  • GEN $83.9M
  • ΔGEN −$44.6M
  • TOP1 29.8%
  • PY 2024

Volume peers

Nearest volume peer: Celgene Corporation ($88.9M)

Abbott Laboratories$91.7MCelgene Corporation$88.9MZimmer Biomet Holdings, Inc.…$88.6MCSL Behring$88.2MIncyte Corporation$84.4M
All-tracks payment totals near Zimmer Biomet Holdings, Inc. (CMS Open Payments PY2024)

Zimmer Biomet Holdings, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Zimmer Biomet Holdings, Inc.'s CMS-reported General Payments decreased by $44.6M (−34.7%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: ZIMMER BIOMET HOLDINGS, INC.PY2023: ZIMMER BIOMET HOLDINGS, INC.PY2024: Zimmer Biomet Holdings, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$128.5MPY2024$83.9M
PY2023
$128,468,493.70
PY2024
$83,904,351.23

What the Data Shows for Zimmer Biomet Holdings, Inc.

CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Zimmer Biomet Holdings, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.

"Acquisitions" leads the 11-category general-payment breakdown below at $40.1M (47.8% of General Payments, 56 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Acquisitions" leads Zimmer Biomet Holdings, Inc.'s 11-category general-payment breakdown at $40.1M, 47.8% of the reported total.

Zimmer Biomet Holdings, Inc. reports 11 general-payment categories - the top three are Acquisitions (47.8%), Royalty or License (33.3%), and Education (7.6%). The remaining 8 categories make up 11.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

Category breadth matters here: Zimmer Biomet Holdings, Inc. files across 11 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.

How Zimmer Biomet Holdings, Inc. divides its payments

General-payment categories, ordered by reported total

1. Acquisitions$40.1M2. Royalty or License$27.9M3. Education$6.4M4. Consulting Fee$4.8M5. Travel and Lodging$2.2M6. Food and Beverage$1.4M7. Space Rental or Facility …$349.3K8. Debt Forgiveness$264.1K9. Compensation for Services…$204.3K10. Grant$179.8K
Payment Type Amount Transactions
Acquisitions $40.1M 56
Royalty or License $27.9M 647
Education $6.4M 2,924
Consulting Fee $4.8M 1,736
Travel and Lodging $2.2M 8,808
Food and Beverage $1.4M 18,994
Space Rental or Facility Fees $349.3K 41
Debt Forgiveness $264.1K 160
Compensation for Services Other Than Consulting $204.3K 27
Grant $179.8K 79
Long-Term Medical Supply or Device Loan $44.3K 24

Recipient Concentration in General Payments

The five largest recipient relationships account for $40,109,576.00 (47.8%) of $83,904,351.23 in this company's General Payments records across 7,888 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Zimmer Biomet Holdings, Inc.

The five named recipients with the highest reported General Payments from this company

Nitin Goyal$25.0MErik Kubiak$7.4MColin Poole$3.2MAaron Hofmann$2.6MJonathan Yerasimides$1.9M
  1. 1

    Nitin Goyal

    $25,000,264.39 across 6 reported transactions

  2. 2

    Erik Kubiak

    $7,390,410.50 across 7 reported transactions

  3. 3

    Colin Poole

    $3,199,557.39 across 2 reported transactions

  4. 4

    Aaron Hofmann

    $2,593,980.00 across 1 reported transactions

  5. 5

    Jonathan Yerasimides

    $1,925,363.72 across 181 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Zimmer Biomet Holdings, Inc. ranks #32 of 1,925 by total payments (top 2% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,018 of 1,838 by HHI (bottom 45% least concentrated), a wider distribution than most similarly sized payers.

022.144.166.288.210221027.510331038.51044Total payments ($M)Concentration (HHI, 0-10,000)
Zimmer Biomet Holdings, Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Zimmer Biomet Holdings, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Zimmer Biomet Holdings, Inc..

Seigla Medical, Inc.

HHI 1032

Qiagen, LLC

HHI 1034

Recor Medical Inc

HHI 1026

PolyMedics Innovations Inc.

HHI 1036

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Zimmer Biomet Holdings, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Zimmer Biomet Holdings, Inc. ranks #32 of 1,925 by all-tracks total payments, led by "Acquisitions".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Zimmer Biomet Holdings, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.